A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...

An England-wide study of 331 rare diseases in over 58 million people co-led by UCL researchers has identified eight rare ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

The EU regulator is reviewing tralokinumab for the treatment of adult patients ... in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and ...

Side effects relating to ozone therapy can vary depending on the type of treatment a person undergoes. People should never inhale ozone. If it enters the mouth, nose, or eyes, it can burn and ...